ConductScience.org, home

Paper36967374

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study.

Eom YH and 3 others. World J Surg Oncol, 2023. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study. Papers, record 36967374. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36967374

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study.
PubMed
Journal
World J Surg Oncol
PubMed
Year
2023
PubMed
Publication types
Multicenter Study, Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.15
iCite
Revised in PubMed
2026-01-27
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Eom YHYong Hwa
2Yoon CIChang Ik
3Kang YJYoung Joon
4Jeon YWYe Won

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Humans
Female
Prognosis
Retrospective Studies
Disease-Free Survival
Neoplasm Recurrence, Local
Erb-b2 Receptor Tyrosine Kinases

Source PubMed

Download CSV of topics

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18416714Survival of first and second primary breast cancer.Cancer1993https://conductscience.org/library/papers/8416714PubMed
225861031Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.PLoS One2015https://conductscience.org/library/papers/25861031PubMed
329719816Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes.Front Oncol2018https://conductscience.org/library/papers/29719816PubMed
428755621Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer.Breast2017https://conductscience.org/library/papers/28755621PubMed
524439313Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.Lancet Oncol2014https://conductscience.org/library/papers/24439313PubMed
621824742
Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Eur J Surg Oncol2011https://conductscience.org/library/papers/21824742PubMed
716859523Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study.Breast Cancer Res2006https://conductscience.org/library/papers/16859523PubMed
82198001Survival following locoregional recurrence after breast conservation therapy for cancer.Ann Surg1990https://conductscience.org/library/papers/2198001PubMed
928109404How could breast cancer molecular features contribute to locoregional treatment decision making?Crit Rev Oncol Hematol2017https://conductscience.org/library/papers/28109404PubMed
1023800672Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients.Eur J Cancer2013https://conductscience.org/library/papers/23800672PubMed
1121900114Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.J Clin Oncol2011https://conductscience.org/library/papers/21900114PubMed
1210764430Role of isolated locoregional recurrence of breast cancer: results of four prospective studies.J Clin Oncol2000https://conductscience.org/library/papers/10764430PubMed
1327494111Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.PLoS One2016https://conductscience.org/library/papers/27494111PubMed
1416648502Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.J Clin Oncol2006https://conductscience.org/library/papers/16648502PubMed
1519349544
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
J Clin Oncol2009https://conductscience.org/library/papers/19349544PubMed
1621523714Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence.Cancer2011https://conductscience.org/library/papers/21523714PubMed
171677695Significance of ipsilateral breast tumour recurrence after lumpectomy.Lancet1991https://conductscience.org/library/papers/1677695PubMed
1812393820Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med2002https://conductscience.org/library/papers/12393820PubMed
1930238274Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.Breast Cancer Res Treat2019https://conductscience.org/library/papers/30238274PubMed
209652841Local and distant recurrence after conservative management of "very low-risk" breast cancer are dependent events: a 10-year follow-up.Int J Radiat Oncol Biol Phys1998https://conductscience.org/library/papers/9652841PubMed

See all 31 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
38727889Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of breast cancer? A population-based, propensity score matched cohort study.Breast Cancer Res Treat2024https://conductscience.org/library/papers/38727889

Source PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36967374

GET https://conductscience.org/api/papers/v1/36967374/references?page=2